Editorial introductions

Abstract

Current Opinion in Hematology was launched in 1994. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of hematology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue. SECTION EDITORS Hal E. BroxmeyerHal E. BroxmeyerDr Hal E. Broxmeyer is a distinguished Professor, Professor of Microbiology and Immunology, Mary Margaret Walther Professor Emeritus, and Co-Leader Program on Hematopoiesis, Malignant Hematology, and Immunology, Indiana University Simon Cancer Center, and former Chairman of Microbiology and Immunology and Scientific Director, Walther Oncology Center, at the Indiana University School of Medicine, Indianapolis, IN, USA. From 1975 to 1983, he worked at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City rising from the rank of Associate Researcher to that of Associate Member. He was also Assistant Professor of Biology, Sloan Kettering Division of Cornell University Graduate School of Medical Sciences, New York, USA, before being recruited to the Indiana University School of Medicine in 1983 as an Associate Professor of Medicine. To date, he has published 764 scientific papers (527 refereed papers and 237 Reviews/Book Chapters). Dr Broxmeyer's laboratory studies mechanisms regulating hematopoietic stem and progenitor cell, embryonic stem cell and induced pluripotent stem cell: proliferation, self-renewal, survival, differentiation and migration (homing/mobilization) and he was involved in establishing the field of cord blood transplantation. Dr Broxmeyer has been the recipient of numerous awards since the 1970's. The more recently include Indiana University School of Medicine Alumni Association (2008); State of Indiana General Assembly House Resolution No. 46 (2008); Mission Advancement Award, Leukemia Lymphoma Society (2008); Cord Blood Pioneering Award, Int. Cord Blood Symposium (2008); Till and McCullough Award, Canadian Bone Marrow Transplant Group (2010); Donald Metcalf Award, Int. Soc. Expt. Hematol. (2011); Elected Fellow of the American Association for the Advancement of Science (AAAS) (2013); and Honorary Professorship, Peking Union Medical College, Beijing, China (2014). Dr Broxmeyer is a Past President of the American Society of Hematology (ASH; 2010), past President of the International Society for Experimental Hematology (ISEH, 1990, 1991), past Chairman, and member, Board of Scientific Councilors, National Space Biomedical Research Institute (NSBRI/NASA, 1998–2006), and Chairman Emeritus, Board of Directors, National Disease Research Interchange, Philadelphia, PA, USA. Ari MelnickAri MelnickAri Melnick, MD, is the Gebroe Family Professor of Hematology/Oncology and a Professor of Medicine and Pharmacology at Weill Cornell Medical College (WCMC) in New York City, USA. He is Chair of the Hematologic Malignancies Program of the Weill Cornell Cancer Center and is also Director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences and Director of the Epigenomics Core Facility, both of which are at WCMC. Dr Melnick was raised in Argentina and received his medical degree from the University of Buenos Aires, Argentina. He completed a residency in internal medicine and a fellowship in hematology/oncology, as well as a postdoctoral fellowship at the Mount Sinai School of Medicine in New York City, USA. Dr Melnick's research interests include the biology and molecular targeting of B-cell lymphomas, targeting transcriptional and epigenetic repressors for cancer therapy, and identifying the epigenetic basis of hematologic malignancies. He and his research associates have also developed novel therapies to correct aberrant transcriptional regulation and signaling in these tumors. Dr Melnick has been Scientific Chair of the American Society of Hematology (ASH) annual meeting and has organized several meetings in the areas of epigenetics and hematologic malignancies. Dr Melnick is a past ASH Faculty Scholar and Kimmel Foundation Scholar, and he has been recognized for this work by the Leukemia & Lymphoma Society. He is also co-leader of the New York Leukemia Working Group. Dr Melnick has authored or coauthored more than 150 published manuscripts in journals such as Nature, Science, Cell, Cancer Cell, Nature Medicine, Nature Immunology, and the New England Journal of Medicine.